BioLife Solutions, Inc. (BLFS)
Automate Your Wheel Strategy on BLFS
With Tiblio's Option Bot, you can configure your own wheel strategy including BLFS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BLFS
- Rev/Share 1.6849
- Book/Share 7.4812
- PB 2.9836
- Debt/Equity 0.0764
- CurrentRatio 4.73
- ROIC -0.0108
- MktCap 1061608789.0
- FreeCF/Share 0.2395
- PFCF 94.0559
- PE -101.0556
- Debt/Assets 0.0682
- DivYield 0
- ROE -0.0309
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | BLFS | H.C. Wainwright | -- | Buy | -- | $29 | Sept. 30, 2024 |
News
Can BioLife Solutions (BLFS) Climb 30.68% to Reach the Level Wall Street Analysts Expect?
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 30.7% upside potential for BioLife Solutions (BLFS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
BioLife Solutions, Inc. (BLFS) Q1 2025 Earnings Call Transcript
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral
BioLife Solutions, Inc. (NASDAQ:BLFS ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Troy Wichterman - Chief Financial Officer Roderick de Greef - Chairman and Chief Executive Officer Conference Call Participants Matthew Stanton - Jefferies Paul Knight - KeyBanc Chad Wiatrowski - TD Cowen Thomas Flaten - Lake Street Matthew Hewitt - Craig-Hallum Capital Group Carl Byrnes - Northland Capital Markets Yi Chen - H.C. Wainwright Operator Good afternoon, ladies and gentlemen, and thank you for standing by.
Read More
BioLife Solutions to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025
Published: April 30, 2025 by: PRNewsWire
Sentiment: Neutral
BOTHELL, Wash. , April 30, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the Company's first quarter 2025 financial results will be released after market close on Thursday, May 8, 2025.
Read More
5 Low-Leverage Stocks to Buy Amid Trump's Tariff Woes
Published: March 24, 2025 by: Zacks Investment Research
Sentiment: Positive
The majority of U.S. stock indices ended barely in the green on March 21, 2025, overcoming their recent losing streaks since investors remain wary about the long-term economic impacts of President Trump's enhanced import tariffs. The latest uptick in the major stock indices was mostly because the Federal Reserve kept its projection for interest rate cuts broadly unchanged, indicating economic stability for the time being.
Read More
5 Low-Leverage Stocks to Buy Amid Volatile Market Sentiment
Published: March 10, 2025 by: Zacks Investment Research
Sentiment: Positive
The crux of safe investment lies in choosing a company that is not burdened with debt. You may buy BLFS, BHLB, NVDA, GBX and EZPW.
Read More
BioLife Solutions, Inc. (BLFS) Reports Q4 Loss, Tops Revenue Estimates
Published: March 03, 2025 by: Zacks Investment Research
Sentiment: Negative
BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.30 per share a year ago.
Read More
BioLife Solutions to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on March 3, 2025
Published: February 20, 2025 by: PRNewsWire
Sentiment: Neutral
BOTHELL, Wash. , Feb. 20, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the 2024 fourth quarter and full year financial results will be released on March 3, 2025 pre-market.
Read More
Recent Price Trend in BioLife Solutions (BLFS) is Your Friend, Here's Why
Published: February 12, 2025 by: Zacks Investment Research
Sentiment: Positive
BioLife Solutions (BLFS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Read More
About BioLife Solutions, Inc. (BLFS)
- IPO Date 1989-11-22
- Website https://www.biolifesolutions.com
- Industry Medical - Instruments & Supplies
- CEO Mr. Roderick de Greef
- Employees 159